亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢楷倫化學新材料有限公司市場  

比馬前列素 阿瑞匹坦及中間體 亞硝基過***鉀 埃索美拉唑鈉及中間體 CB-03-1

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:江君
  • 電話:027-87773372
  • 郵件:2513471628@qq.com
  • QQ:2513471628
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 3,5-二甲基金剛胺***
3,5-二甲基金剛胺***
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
過期 長期有效
更新 2019-06-28 09:56
 
詳細信息
 3,5-二甲基金剛胺***
英文名:Memantine hydrochloride
別  名:3,5-二甲基金剛胺***;美金剛胺***;
1.3-Dimethylaminoadamantane hydrochloride;3.5-Dimethyl-1-aminoadamantane hydrochloride
化學名:3,5-Dimethyltricyclo(3.3.1.1(3.7)) decan-1-amine hydrochloride 
分子式:C12H21N·HCl
分之量:215.81
CAS號:41100-52-1
外  觀:白色或類白色結晶或粉末
熔  點:290~295°C
含  量:≥99%
包  裝:可以根據客戶的需要進行包裝
無定型結晶,熔點:340度分解。2,含水結晶:熔點:260--270度。
標  準:USP標準
©2025 武漢楷倫化學新材料有限公司市場 版權所有   技術支持:化工網   訪問量:10637  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |